Shopping Cart
- Remove All
Your shopping cart is currently empty
HSK0935 is a highly selective and orally available SGLT2 inhibitor (IC50: 1.3 nM). It has antihyperglycemic activities.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,420 | 6-8 weeks | |
| 50 mg | $1,850 | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks |
| Description | HSK0935 is a highly selective and orally available SGLT2 inhibitor (IC50: 1.3 nM). It has antihyperglycemic activities. |
| Targets&IC50 | SGLT2:1.3 nM |
| In vitro | HSK0935 shows excellent hSGLT2 inhibition of 1.3 nM. HSK0935 displays a high hSGLT1/hSGLT2 selectivity of 843-fold[1]. |
| In vivo | In a 28-day repeat-dose toxicology study conducted on beagle dogs, HSK0935 was found to be well-tolerated at doses up to 300 mg/kg, without causing any deaths or severe adverse effects. Additionally, treatment with HSK0935 at doses of 1, 3, and 10 mg/kg resulted in significant urinary glucose excretion in Sprague-Dawley (SD) rats, and had an even greater effect on urinary glucose excretion in Rhesus monkeys[1]. |
| Synonyms | HSK-0935, HSK 0935 |
| Molecular Weight | 436.88 |
| Formula | C22H25ClO7 |
| Cas No. | 1638851-44-1 |
| Relative Density. | 1.43 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.